These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 12164480)

  • 1. Engineering antibodies for therapy.
    Presta LG
    Curr Pharm Biotechnol; 2002 Sep; 3(3):237-56. PubMed ID: 12164480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
    Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
    Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
    Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
    MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards an immunotherapy for p185HER2 overexpressing tumors.
    Carter P; Rodrigues ML; Lewis GD; Figari I; Shalaby MR
    Adv Exp Med Biol; 1994; 353():83-94. PubMed ID: 7985544
    [No Abstract]   [Full Text] [Related]  

  • 5. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
    Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
    Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
    Vincent KJ; Zurini M
    Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic monoclonal antibodies: a little history, a lot of engineering, and... some clinical successes].
    Siberil S; Dutertre CA; Boix C; Teillaud JL
    Transfus Clin Biol; 2005 Jun; 12(2):114-22. PubMed ID: 15907389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.
    Stockmeyer B; Dechant M; van Egmond M; Tutt AL; Sundarapandiyan K; Graziano RF; Repp R; Kalden JR; Gramatzki M; Glennie MJ; van de Winkel JG; Valerius T
    J Immunol; 2000 Nov; 165(10):5954-61. PubMed ID: 11067958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Engineering Antibodies as Drugs: Principles and Practice].
    Lugovskoy AA
    Mol Biol (Mosk); 2017; 51(6):886-898. PubMed ID: 29271954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering antibodies for therapy.
    Adair JR
    Immunol Rev; 1992 Dec; 130():5-40. PubMed ID: 1286872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
    Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
    MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toward Drug-Like Multispecific Antibodies by Design.
    Sawant MS; Streu CN; Wu L; Tessier PM
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.
    Huang S; Li F; Liu H; Ye P; Fan X; Yuan X; Wu Z; Chen J; Jin C; Shen B; Feng J; Zhang B
    MAbs; 2018; 10(6):864-875. PubMed ID: 30081724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function.
    Derer S; Kellner C; Berger S; Valerius T; Peipp M
    Methods Mol Biol; 2012; 907():519-36. PubMed ID: 22907372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential therapeutic roles for antibody mixtures.
    Raju TS; Strohl WR
    Expert Opin Biol Ther; 2013 Oct; 13(10):1347-52. PubMed ID: 23886377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges.
    Teillaud JL
    Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S15-27. PubMed ID: 16187937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoglobulin isotype knowledge and application to Fc engineering.
    Brezski RJ; Georgiou G
    Curr Opin Immunol; 2016 Jun; 40():62-9. PubMed ID: 27003675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2.
    Wels W; Groner B; Hynes NE
    Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():113-28. PubMed ID: 8815001
    [No Abstract]   [Full Text] [Related]  

  • 20. Diabodies: small bispecific antibody fragments.
    Holliger P; Winter G
    Cancer Immunol Immunother; 1997; 45(3-4):128-30. PubMed ID: 9435855
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.